An 8 Week, Randomized, Double-Blind, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of Oral IPL512,602 [Inflazyme Pharmaceuticals] to Placebo in Subjects With Moderate to Severe Persistent Asthma Inadequately Controlled on Inhaled Corticosteroids

Trial Profile

An 8 Week, Randomized, Double-Blind, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of Oral IPL512,602 [Inflazyme Pharmaceuticals] to Placebo in Subjects With Moderate to Severe Persistent Asthma Inadequately Controlled on Inhaled Corticosteroids

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs IPL 512602 (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms CAPSICS
  • Sponsors Inflazyme Pharmaceuticals
  • Most Recent Events

    • 24 Apr 2014 Last checked against ClinicalTrial.gov record.
    • 24 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top